Eagle Pharmaceuticals, Inc. (1E6.F)
| Previous close | 4.1400 |
| Open | 3.9000 |
| Bid | 3.7800 x 20000 |
| Ask | 3.8600 x 20000 |
| Day's range | 3.9000 - 3.9000 |
| 52-week range | 3.8000 - 27.0000 |
| Volume | |
| Avg. volume | 22 |
| Market cap | 50.537M |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 4.94 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Zacks
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
